Study on Pattern and Prevalence of Dyslipidemia and Other Cardiovascular Risk Factors among the Various Ethnic Groups of Trinidad and Tobago

Background: Dyslipidemia is a crucial component of the metabolic syndrome and has long been linked to the development of issues such as cardiovascular disease (CVD). In addition, there have been reports of differences…

Determining the Factors Associated with Prognosis of Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a condition that occurs at the intersection of obesity, metabolic syndrome, and liver failure. Metformin’s role in individuals with non-alcoholic fatty liver disease has been explored in…

Determination of Diabetes and Dyslipidemia Goals in the Management of Diabetes

Diabetes Type I and Type II have an increased risk of early atherosclerotic CVD, such as CHD and PAD [1], and it is well known that glucose control improves TG levels and cholesterol-lowering…

Encapsulation of Anti-dyslipidemic Drug as a Controlled Release Tablet Using Proanthocyanidin Polymer

Many people today are at high risk of coronary heart disease, and few drugs are available to assist them achieve their lipid goals. Niacin is one of the most promising drugs for dyslipidemia,…